drugset / Trial / NCT01829841
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Phase 2
Completed
150 enrolled
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
* Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. * The purpose of this study is to compare the efficacy and safety profile between Famitinib and Sunitinib in patients with metastatic renal cell carcinoma.
Timeline
- Start
- 2011-05
- Primary completion
- 2013-04
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | 25 mg | Oral |
| Comparator | Sunitinib | Small molecule | 50 mg | Oral |